Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide ... and claiming that the prices of GLP-1 drugs for weight loss are five ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have ... and Eli Lilly's tirzepatide for diabetes and obesity to 'usual care' – in other words other standard drug ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...